Investments
Spark Therapeutics drops as hemophilia gene therapy trial disappoints
Shares of biotechnology company Spark Therapeutics slid nearly 30 percent Tuesday after the company reported the results of a small trial for an experimental gene therapy treatment for hemophilia that reduced bleeds in most patients […]